DNA repair is a key determinant in the cellular response to therapy and tumor repair status could play an important role in tailoring patient therapy. Our goal was to evaluate the mRNA of 13 genes involved in different DNA repair pathways (base excision, nucleotide excision, homologous recombination, and Fanconi anemia) in paraffin embedded samples of triple negative breast cancer (TNBC) compared to luminal A breast cancer (LABC). Most of the genes involved in nucleotide excision repair and Fanconi Anemia pathways, and CHK1 gene were significantly less expressed in TNBC than in LABC. PARP1 levels were higher in TNBC than in LABC. In univariate analysis high level of FANCA correlated with an increased overall survival and event free survival...
Triple-negative breast cancer (TNBC) patients exhibiting pathological complete response (pCR) have b...
Triple-negative breast cancer (TNBC) presents a marked diversity at the molecular level, which promo...
DNA repair defects have been increasingly focused on as therapeutic targets. In hormone-positive bre...
DNA repair is a key determinant in the cellular response to therapy and tumor repair status could pl...
Abstract Triple Negative Breast Cancer (TNBC), negative for estrogen, progesterone and Her2 receptor...
Breast cancer (BC) is a heterogeneous disease which many studies have classified in at least four mo...
Triple negative (TN) breast cancers make up some 15% of all breast cancers. Approximately 10-15% are...
Triple negative (TN) breast cancers make up some 15% of all breast cancers. Approximately 10-15% are...
Impaired DNA repair drives mutagenicity, which increases neoantigen load and immunogenicity. We inve...
Patients with triple negative breast cancer (TNBC) tend to have poor outcomes compared to other subt...
Triple negative breast cancers (TNBCs) represent about 15–20% of all breast cancer cases and are cha...
Abstract Triple-negative breast cancer (TNBC) is an aggressive subtype of breast cancer tumors. Comp...
Triple negative breast cancer (TNBC), defined by the lack of expression of the estrogen receptor, pr...
Stratification of oestrogen receptor (ER) negative and triple negative breast cancers (TNBCs) is urg...
Triple-negative breast cancer (TNBC), which accounts for approximately 15–20% of all breast cancers,...
Triple-negative breast cancer (TNBC) patients exhibiting pathological complete response (pCR) have b...
Triple-negative breast cancer (TNBC) presents a marked diversity at the molecular level, which promo...
DNA repair defects have been increasingly focused on as therapeutic targets. In hormone-positive bre...
DNA repair is a key determinant in the cellular response to therapy and tumor repair status could pl...
Abstract Triple Negative Breast Cancer (TNBC), negative for estrogen, progesterone and Her2 receptor...
Breast cancer (BC) is a heterogeneous disease which many studies have classified in at least four mo...
Triple negative (TN) breast cancers make up some 15% of all breast cancers. Approximately 10-15% are...
Triple negative (TN) breast cancers make up some 15% of all breast cancers. Approximately 10-15% are...
Impaired DNA repair drives mutagenicity, which increases neoantigen load and immunogenicity. We inve...
Patients with triple negative breast cancer (TNBC) tend to have poor outcomes compared to other subt...
Triple negative breast cancers (TNBCs) represent about 15–20% of all breast cancer cases and are cha...
Abstract Triple-negative breast cancer (TNBC) is an aggressive subtype of breast cancer tumors. Comp...
Triple negative breast cancer (TNBC), defined by the lack of expression of the estrogen receptor, pr...
Stratification of oestrogen receptor (ER) negative and triple negative breast cancers (TNBCs) is urg...
Triple-negative breast cancer (TNBC), which accounts for approximately 15–20% of all breast cancers,...
Triple-negative breast cancer (TNBC) patients exhibiting pathological complete response (pCR) have b...
Triple-negative breast cancer (TNBC) presents a marked diversity at the molecular level, which promo...
DNA repair defects have been increasingly focused on as therapeutic targets. In hormone-positive bre...